Tim Boyd

Tim Boyd

Company: Partner Tx

Job title: Director of Development


Sargramostim as a Vaccine Adjuvant 9:30 am

GM-CSF induction of non-lymphoid tissue-resident dendritic cells (DCs) is imperative for CD8+ T cell responses, leading to a history of GM-CSF use as an adjuvant in numerous vaccines. Studies have reported both increased immune responses and immune suppression, depending upon GM-CSF dosage and frequency. Concurrent strategies to suppress immunoregulatory cells may enhance GMCSF- mediated DC…Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.